QIAGEN’s German Exchange Performance: 5‑Year Decline, Strong Market Cap & Biopharma Growth Strategy
Explore QIAGEN’s biopharma value: despite a 5‑year price dip, its €7.3bn market cap, strong diagnostics tech, and strategic M&A moves keep it a key precision‑medicine player.
5 minutes to read










